Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

variety of cancers had been treated with OGX-427 as a single agent in a dose escalation Phase 1 trial. OGX-427 was well tolerated. Declines in circulating tumor cells (CTCs), an emerging metric to assess treatment effect, have been observed at all dose levels. Changes in tumor markers (i.e declines of PSA, CA-125) have also been observed. Reductions in CTCs and tumor markers both suggest single-agent activity.

The abstract represents preliminary data on OGX-427 as a single agent. Updated data will be presented during an oral presentation at ASCO.

The oral presentations are scheduled to be held as shown below at the ASCO Annual Meeting in Orlando, Florida.

    Presentation Information

    Title:    Mature results of a randomized phase II study of OGX-011 in
              combination with docetaxel/prednisone versus
              docetaxel/prednisone in patients with metastatic castration
              resistant prostate cancer
    Authors:  K. N. Chi, S. J. Hotte, E. Yu, D. Tu, B. Eigl, I. Tannock, F.
              Saad, S. North, J. Powers, E. Eisenhauer, National Cancer
              Institute of Canada Clinical Trials Group
    Date:     4:30 p.m. - 4:45 p.m. EDT, Saturday, May 30, 2009
    Location: Level 3, Chapin Theatre, W320, Orange County Convention Center
    Abstract: # 5012
    Title:    OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO),
              against HSP27: Results of a first-in-human trial
    Authors:  S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S.Higano, M. Gleave, K.
              N. Chi
    Date:     2:00 p.m. - 2:15 p.m. EDT, Saturday, May 30, 2009
    Location: Level 4, Valencia Room, W415A, Orange County Convention Center
    Abstract: # 3506

    About OGX-011

OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance and is currently being evaluated in Phase 2 clinical trials in prostate, lung
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 26, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Molecular ... to their offering. This report ... that will play an important role in ... forensics and biological warfare in the 21st ...
(Date:5/27/2015)... Expanding in a big way into the ... Inc. recently inked a deal with Arthur Mokuda, ... , the largest endodontic distributor in Japan. The move ... Avalon Biomed, which manufactures Grey MTA Plus® and the ... that have won renown from dentists around the world. ...
(Date:5/27/2015)... 2015 The ALS Therapy Development ... wholly owned subsidiary, Anelixis Therapeutics , $1.5 million ... that targets the innate immune system. The funding comes ... received from the 2014 social media phenomenon known as ... $4 million raised directly by the Institute through last ...
(Date:5/27/2015)... , May 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... DCVax® personalized immune therapies for cancer, announced today that ... of the Company, will be making an Industry Expert ... Chicago on Saturday, May 30, ... Industry Expert Theater in McCormick Place. Dr. ...
Breaking Biology Technology:Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3
... Dec. 27, 2011  United Therapeutics Corporation (NASDAQ: ... Therapeutics Europe, Ltd., announced today that the French ... des Produits de Sante (AFSSAPS) has approved ... of pulmonary arterial hypertension (PAH).  Remodulin is already ...
... Pacific Meso Center (PMC) at the Pacific Heart, ... of $100,000 from Roger and Ann Worthington. Mr. Worthington ... Roger G. Worthington, PC, an asbestos law firm in ... laboratory in Santa Monica, California. The new state-of-the-art mesothelioma ...
... Inc. (Inspiration), the only biopharmaceutical company focused exclusively ... options for people with hemophilia, announced today the ... MA from Laguna Niguel, CA.  The move is ... future staffing and facility needs as the Company ...
Cached Biology Technology:Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 2Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 3Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 4Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 5Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles 2Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts 2Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts 3
(Date:5/26/2015)... , May 26, 2015 ... announced the addition of the "Saudi Arabia ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Arabia is projected to grow at ... high growth is attributed to the surging demand ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... A group of Texas-based researchers provided answers for the ... very short window by the U.S. Environmental Protection Agency ... The EPA issued a final ruling on Dec. 18 ... these gases by large confined animal feeding operations to ...
... screwing up your responsibility by firing science and environment ... do this," said climate researcher and policy analyst Stephen ... of global warming and related issues. Schneider, a coordinating ... the Intergovernmental Panel on Climate Change published in 2007, ...
... Our ability to conserve and protect wildlife is at ... environment is changing over time,says new research out today ... shows that people may not realise species are declining ... changed,dramatically since their parents, and grandparents, days, and even ...
Cached Biology News:Texas researchers provide emissions data for livestock industry 2Texas researchers provide emissions data for livestock industry 3Texas researchers provide emissions data for livestock industry 4Mass media often failing in its coverage of global warming, says climate researcher 2Mass media often failing in its coverage of global warming, says climate researcher 3Village bird study highlights loss of wildlife knowledge from one 2Village bird study highlights loss of wildlife knowledge from one 3
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... is designed for stabilizing the coating ... for immunoassay development. It can ... coating and drying process and for ... also works as a blocking agent ...
... Digital shaking water bath, with a comprehensive ... and shaking water baths with seamless, splash-water ... The bright MULTI-DISPLAY (LED) indicating up to ... the lab. Advanced MICROPROCESSOR technology with PID ...
... new TC-412 thermal cycler, flexible on your protocols, ... a high performance, high sample throughput instrument at ... Flexible block format: The truly user-friendly fully ... in a matter of seconds without the need ...
Biology Products: